

**MINIMAL RESIDUAL
DISEASE IN ACUTE
LEUKEMIA**B. Löwenberg, A. Hagenbeek
(editors)

Martinus Nijhoff Publishers

Softcover reprint of the original 1st ed.
1984, 416 p. 17 illus.**Printed book**

Softcover

89,99 € | £79.99 | \$109.99

^[1]96,29 € (D) | 98,99 € (A) | CHF
106,50**eBook**

74,96 € | £63.99 | \$84.99

^[2]74,96 € (D) | 74,96 € (A) | CHF
85,00Available from your library or
springer.com/shop**MyCopy ^[3]**

Printed eBook for just

€ | \$ 24.99

springer.com/mycopy

B. Löwenberg, A. Hagenbeek (Eds.)

Minimal Residual Disease in Acute Leukemia

Series: Developments in Oncology

The objective of the treatment of acute leukemia involves the eradication of all neoplastic cells, including the last one. Ideally, treatment should be controlled by monitoring cell kill. If the last cells could be discovered and their biological properties be determined, the qualitative and quantitative effects of treatment should be directly evaluable. This should ultimately permit a calculated tumor cell reduction thereby avoiding overtreatment and excessive toxicity and thus providing a basis for individualized antileukemic treatment. In recent years several new developments have contributed to the selective discovery of minimal numbers of leukemic cells which are hidden among the normal cells in the marrow cavities. These methods are the first steps to the realization of the therapeutic goals indicated above. They include the production and application of monoclonal antibodies against differentiation antigens on the cell surface, the use of pulse cytophotometry - and cell sorter techniques, the employment of cytogenetics, the development of culture techniques for selective growth of precursor cells and several others. These methodologies offer prospects for refined diagnosis and, as far as the elimination of leukemic cells is concerned, the further development of autologous bone marrow transplantation. Eliminating tumor cells from autologous grafts requires the detailed knowledge of the cellular inter-relationships within the neoplasm so that the neoplastic cells responsible for tumor propagation are specifically removed. Recognition and characterization of the clonogenic cells of the neoplasm should then lead to determining their sensitivity to the therapeutic agents which are clinically applied.

Order online at springer.com / or for the Americas call (toll free) 1-800-SPRINGER / or email us at: customerservice@springernature.com. / For outside the Americas call +49 (0) 6221-345-4301 / or email us at: customerservice@springernature.com.

The first € price and the £ and \$ price are net prices, subject to local VAT. Prices indicated with [1] include VAT for books; the €(D) includes 7% for Germany, the €(A) includes 10% for Austria. Prices indicated with [2] include VAT for electronic products; 19% for Germany, 20% for Austria. All prices exclusive of carriage charges. Prices and other details are subject to change without notice. All errors and omissions excepted. [3] No discount for MyCopy.

